Barcelona, February 9th, 2021. We are pleased to announce the launch of Angiolite DES new long lengths, for the treatment of long lesions. The 44 and 49 mm sizes received the CE Mark approval for the treatment of diffuse lesions. With the launch of these lengths Angiolite is one of the DES with longer lengths of the market.
These new lengths will facilitate the treatment of long lesions in the coronary arteries. The 44 and 49mm lengths can help to reduce cost and increase procedural efficiency, avoiding complications such as stents overlapping, and less intervention time vs the use of more than one DES.
Angiolite is now one of the few DES offering 44 and 49mm lengths for 2.50, 2.75, 3.0, 3.5, 4.0 diameters.
The objective of iVascular with Angiolite 44 and 49 mm DES is to bring value to the clinical daily practice of physicians, in order to enhance the outcomes of complex procedures, such as long lesions.
Angiolite is a DES, indicated for patients with symptomatic ischemic heart disease due to “de novo” stenotic and re-stenotic lesions and patients with occlusive disease due to acute myocardial infarction. It has been specifically designed, and feature alternating links to achieve a homogeneous arterial coverage with high rates of endothelialization due to its fluorinated polymer and TransferWise, proprietary iVascular nanotechnology.
Lear more about Angiolite and its clinical evidence.